Look Beyond Email
Ushering a manuscript from concept through to submission to a scientific/medical journal or to a medical congress can be an unruly and protracted process akin to the proverbial challenge of herding cats.
Internal and external authors need to be able to collaborate and access source information; project managers must be able to track and control multiple, ever-changing drafts; and all contributors must be held to deadlines. And, all the while, the content must be secure (protected from hacking), and every step of the process must be documented and traceable.
While theoretically it may be possible to do some this within an e-mail application, the process really demands the use of specialized document management software.
Address Key Industry Standards
The International Society for Medical Publication Professionals (ISMPP) has published Good Publication Practices (GPP) expending upon the guidance provided by the International Committee of Medical Journal Editors (ICMJE), which stipulates, “Companies should have policies and procedures in place to document the complete process of publication and presentation development and ensure maintenance of shareable data that could be requested after publication.”[1] ISMPP clarifies that the documents that should be retained include[2]:
- All study-related data that support the publication (in shareable format)
- Author agreements to participate in the publication development process
- Details on the intellectual input and other contributions, including comments on drafts
- Versions of the draft to document how comments were incorporated
- A list of contributors other than authors who were allowed to review or comment
- The decision on who would submit the abstract or manuscript
- Authors’ approvals on the final version
- Disclosures from all authors a listing of who contributed what
- Journal or congress peer-reviewer comments and the authors’ responses
Additionally, compliance with ICJME, GPP, and the US Office of the Inspector General requires that author comments be time-stamped.
An electronic archiving system can serve as the repository for all of these project documents, making retrieval and tracking a simple matter. It can also provide an audit trail, with time stamps applied to each action/comment entered by authors and reviewers.
Help Your Authors Adhere to Key Timelines
During an ICON webinar on publishing best practices, we asked participants to name their biggest challenge in working with authors (from among a set of choices). The overwhelming majority (90 percent) answered, “Getting authors to be adhere to timelines.” The right automated system can help with this in a number of ways by providing:
- Streamlined communications among participants
- Visual timelines and automated workflows
- Automatic email reminders with a direct link to the required task
- Step-by-step instructions for each task
- Progress dashboards and robust reports
Of course, for a system to be helpful, it must not only have the right functionality, but it must be easy to use. Especially in situations in which you will have external participants, the system must be intuitive; if it is difficult to use, users will attempt to work outside of the system, defeating the purpose.
For more information on how to technology can support the manuscript development process, visit the PubsHub section of the site.
References:
[1] International Committee of Medical Journal Editors, “Guiding principles for the development of policies on sharing clinical trials data,” (January 2014) Accessed at www.icmje.org/news-and-editorials/principles_data_sharing_jan2014.html on 8 May 2015.
[2] Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Com
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel